Abstract

Anti-cancer therapies based on oncolytic viruses are emerging as important approaches in cancer treatment. However, the effectiveness of these therapies depends significantly on the interactions between the oncolytic viruses and the host immune response. Macrophages are one of the most important cell types in the anti-viral immune responses, by acting as a first line of defence against infections. Here, we consider a mathematical approach to investigate the possible outcomes of the interactions between two extreme phenotypes of macrophages (M1 and M2 cells) and an oncolytic virus (VSV), in the context of B16F10 melanoma. We show that polarization towards either an M1 or M2 phenotype can enhance oncolytic virus therapy through either (i) anti-tumour immune activation, or (ii) enhanced oncolysis. Moreover, we show that tumour reduction and elimination does not depend only on the ratio of M1:M2 cells, but also on the number of tumour-infiltrating macrophages.